Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase-Reference-Cited by-同舟云学术

Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase

Published:2023-09 Issue: Volume:257 Page:115532
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Lin Fengwei,Sun Ming,Gao Jun,Zhang Bing,Mao Qing,Bao Ziyang,Shen Chao,Li Qiuhua,Wang Han,Wang Shaojie

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference47 articles.

1. PEG-uricase in the management of treatment-resistant gout and hyperuricemia;Sherman;Adv. Drug Deliv. Rev.,2008

2. Physiological functions and pathogenic potential of uric acid: a review;El Ridi;J. Adv. Res.,2017

3. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets;Punzi;Autoimmun. Rev.,2012

4. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout;Tan;Sci. Rep.,2017

5. Urate handling in the human body;Hyndman;Curr. Rheumatol. Rep.,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout;Journal of Medicinal Chemistry;2024-08-07

2. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia;Bioorganic Chemistry;2024-06

3. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities;European Journal of Medicinal Chemistry;2024-04

4. Heterocyclic compounds as xanthine oxidase inhibitors for the management of hyperuricemia: synthetic strategies, structure–activity relationship and molecular docking studies (2018–2024);RSC Medicinal Chemistry;2024